Category: AbbVie

Media Release COPENHAGEN, Denmark; June 9, 2023, at 9:00am CEST Results from phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab in combination with rituximab-lenalidomide (R2) showed a 98 percent overall response rate (ORR), 87 percent complete metabolic response (CMR) in patients with relapsed or refractory (R/R) follicular lymphoma (FL) Results from…

COPENHAGEN, Denmark–(BUSINESS WIRE)– Genmab A/S (Nasdaq: GMAB) today announced data from its ongoing phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab-lenalidomide (R2) showed an overall response rate (ORR) of 98 percent and complete metabolic response (CMR) of 87 percent in…

PRESS RELEASE Published June 8, 2023 Biotechnology is the application of scientific and engineering principles to the processing of materials by biological agents to provide goods and services. Today, biotechnology is being used to create new and improved crop varieties, develop renewable fuels, and create new industrial and consumer products….

LL28 Coherus Biosciences (NASDAQ:CHRS) reported promising overall survival data from a Phase 3 study for its drug candidate toripalimab in the treatment of an aggressive head and neck cancer. The study tested toripalimab in combination with the chemotherapy drugs gemcitabine and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma….

Source/Disclosures Published by: Source: Shah NN, et al. Abstract 7554. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: Adaptive Biotechnology and a grant from the Froedtert Foundation supported this study. Shah reports consultant/advisory board roles with, research funding/paid expenses from or stock ownership in Adaptive…

Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 program comprising the REVISIT (NCT03329092) and ASSEMBLE (NCT03580044) studies evaluating…

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 program comprising the REVISIT (NCT03329092) and ASSEMBLE (NCT03580044) studies evaluating the efficacy, safety, and tolerability of the novel investigational antibiotic combination aztreonam-avibactam (ATM-AVI) in treating serious bacterial infections due to Gram-negative bacteria, including metallo-β-lactamase (MBL)-producing multidrug-resistant pathogens for…

By Colin Kellaher Pfizer on Thursday reported positive results from a pair of Phase 3 studies evaluating the efficacy, safety and tolerability of the novel investigational antibiotic combination aztreonam-avibactam, or ATM-AVI. The New York drugmaker, which is studying the combination in the treatment of serious bacterial infections due to antibiotic-resistant…

Spectronaut® 18 makes DIA proteomics projects more efficient and scalable than ever for all mass spectrometry instrument types Novel research with TrueDiscovery™ and TrueTarget™ demonstrates the unique capabilities and utility of mass spectrometry proteomics for biomarker and drug discovery Biognosys’ iRT Kit is recommended for real-time system suitability monitoring in…

NORTH CHICAGO – AbbVie (NYSE: ABBV) today announced the New England Journal of Medicine (NEJM) published results from the pivotal Phase 3 clinical trials – U-EXCEL, U-EXCEED and U-ENDURE evaluating upadacitinib (RINVOQ) in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response…

A few successful drugs are all that are required for a biotech company to shine. We saw this happen with Moderna, a biotech company that grew from $4 billion to $52 billion in market capitalization. Its stock price has risen by 100% in the last three years, owing to the…

F. Hoffmann-La Roche Ltd Basel, 26 May 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) will be presenting new data on six approved and investigational medicines across ten cancer types at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held 2 – 6 June. Highlights include new data…

The UKB is approved by the North West Multi-centre Research Ethics Committee (www.ukbiobank.ac.uk/learn-more-about-uk-biobank/about-us/ethics). The current study was conducted under UKB application no. 26041. The data in the UKB were collected after written informed consent was obtained from all participants. The Human Research Committee of the MGB approved the Biobank research…

Media Release COPENHAGEN, Denmark; May 25, 2023 Oral presentations will highlight epcoritamab–bysp in combination with rituximab–lenalidomide (R2) in high-risk follicular lymphoma Poster presentations will highlight epcoritamab in lymphoma across multiple lines of therapy and histologies where high unmet needs exist Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating…

DLBCL is a highly aggressive malignancy and is the most common type of non-Hodgkin lymphoma (NHL) worldwide. Credit: David A Litman via Shutterstock. AbbVie and Genmab have announced accelerated FDA approval for their bispecific T-cell engager (BiTE) Epkinly (epcoritamab-bysp) for the treatment of relapsed or refractory (R/R) diffuse large B-cell…

NORTH CHICAGO, Ill., May 25, 2023 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced the New England Journal of Medicine (NEJM) published results from the pivotal Phase 3 clinical trials – U-EXCEL, U-EXCEED and U-ENDURE – evaluating upadacitinib (RINVOQ®) in adult patients with moderately to severely active Crohn’s disease who have…

As of May 25, 2023, Upadacitinib, also known as RINVOQ®, has been extensively studied in Phase 3 clinical trials for its effectiveness in treating Crohn’s disease. The trials, which included two induction studies (U-EXCEL and U-EXCEED) and one maintenance study (U-ENDURE), compared the safety and efficacy of upadacitinib to a…

By Niomi Peckham, director, biologics pipeline development, Science-Global Biologics, United States Pharmacopeia The therapeutic potential of monoclonal antibodies (mAbs) came to the fore in the early 1970s when it was first demonstrated that pure protein could be obtained by fusing myeloma cells with the spleen cells of a mouse immunized…

South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has obtained product approval from the US Food and Drug Administration for its biosimilar of the autoimmune disease treatment drug Humira (adalimumab) called CT-P17 (brand name: Yuflyma). As a result, Celltrion will be able to sell Yuflyma for the…

Abbvie-Genmab’s EPKINLY, the first CD20XCD3 Bispecific Antibody gets US approval for Relapsed/Refractory DLBCL treatment. Roche’s Glofitamab is expected to garner benefits in Europe first. Let’s have a glimpse of evolving DLBCL treatment landscape in Relapsed/Refractory setting and if bi-specific as a class can be a threat to CAR-Ts, which already…

Company Logo Dublin, May 23, 2023 (GLOBE NEWSWIRE) — The “Richter’s Syndrome – Pipeline Insight, 2023” clinical trials has been added to ResearchAndMarkets.com‘s offering. This report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Richter’s Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and…

Dublin, May 23, 2023 (GLOBE NEWSWIRE) — The “Richter’s Syndrome – Pipeline Insight, 2023” clinical trials has been added to ResearchAndMarkets.com‘s offering. This report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Richter’s Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage…

The approval was based on results from the Phase 1/2 EPCORE NHL-1 trial, which enrolled 157 patients with large B-cell lymphoma, which included 148 patients with DLBCL or high-grade B-cell lymphoma EPKINLY is a prescription medicine used to treat adults with certain types of DLBCL and HGBL patients. (Credit: AbbVie…

Epkinly is indicated to treat relapsed or refractory diffuse large B-cell lymphoma in adult patients. Credit: CoRus13/ commons.wikimedia.org. The US Food and Drug Administration (FDA) has granted approval to AbbVie and Genmab‘s Epkinly (epcoritamab-bysp) to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in adult patients. Epkinly has…

AbbVie and Genmab’s blood cancer therapy, Epkinly (epcoritamab-bysp), has been granted accelerated approval by the US Food and Drug Administration (FDA). The authorisation specifically applies to adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have received at least two prior lines of treatment. DLBCL is the…

AbbVie (ABBV Quick QuoteABBV – Free Report) and partner Genmab (GMAB Quick QuoteGMAB – Free Report) announced that the FDA has granted accelerated approval to their T-cell engaging bispecific antibody epcoritamab for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The new drug will be marketed by the trade name of…

AbbVie ABBV and partner Genmab GMAB announced that the FDA has granted accelerated approval to their T-cell engaging bispecific antibody epcoritamab for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The new drug will be marketed by the trade name of Epkinly.  Continued approval for this indication will be based on data…

Pictured: Front of FDA headquarters/Grandbrothers/Adobe Stock Friday, AbbVie and Genmab won the FDA’s greenlight for their bi-specific T-cell engager epcoritamab-bysp, now with the brand name Epkinly, for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults. Epkinly was approved under the regulator’s accelerated pathway and is…

AbbVie and partner Genmab have FDA approval for the lead drug in their $3.9 billion cancer partnership, with bispecific antibody Epkinly now cleared as a treatment for diffuse large B-cell lymphoma (DLBCL). Epkinly (epcoritamab) is a CD20xCD3 bispecific and, according to its developers, is the “first and only” T-cell engager…

The US Food and Drug Administration (FDA) on Friday approved Epkinly (epcoritamab-bysp), which is being is co-developed by US pharma major AbbVie (NYSE: ABBV) and Denmark’s Genmab (Nasdaq: GMAB) as part of the companies’ oncology collaboration, worth a potential $3.15 to the latter. AbbVie’s shares edged up 1.2% to $145.11…

FDA Approves Epkinly (epcoritamab-bysp) Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) NORTH CHICAGO, Ill., May 19, 2023 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Epkinly (epcoritamab-bysp), as the first and only T-cell…

Company Announcement Results from phase 2 clinical trial demonstrated EPKINLY™ (epcoritamab-bysp) delivered 61 percent overall response rate, 38 percent complete response, and 15.6-month median duration of response in challenging-to-treat R/R DLBCL patients EPKINLY represents the seventh approved medicine incorporating Genmab (NASDAQ:) innovation and third created via Genmab’s DuoBody® technology platform…

The FDA today approved the T-cell engaging bispecific antibody epcoritamab-bysp for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including those with DLBCL arising from indolent lymphoma or high-grade B-cell lymphoma. Epcoritamab, to be marketed as Epkinly, will be available…

On May 19, 2023, EPKINLY (epcoritamab-bysp) was granted approval by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma (HGBL), after two or more lines…

The FDA has approved the first T-cell–engaging bispecific antibody, epcoritamab-bysp (Epkinly), for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma (HGBCL), after 2 or more lines of systemic therapies.1,2 It is recommended…

JHVEPhoto AbbVie (NYSE:ABBV) and Genmab A/S (GMAB) announced Friday that the FDA approved Epkinly, a bispecific antibody therapy, as a late-line option for adults with white blood cell cancer large B-cell lymphoma (DLBCL). Specifically, the FDA’s label for Epkinly allows its use following two or more lines of systemic therapy…

The FDA has approved epcoritamab-bysp (Epkinly; AbbVie) as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B–cell lymphoma (HGBL) after 2 or more lines…

The US Food and Drug Administration approved epcoritamab (DuoBody, AbbVie and GenMab) today for adults with relapsed/refractory diffuse large B-cell lymphoma following at least two lines of systemic therapy. This includes patients with diffuse large B-cell lymphoma arising from indolent lymphoma and high-grade B-cell lymphoma. Epcoritamab is the first subcutaneous…

ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process your request. Please try again later….

The FDA granted accelerated approval to epcoritamab (Epkinly) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B‑cell lymphoma on Friday. The approval allows the drug’s use after two or more lines of systemic therapy in patients with relapsed or refractory DLBCL, not…

The newly approved treatment, subcutaneous epcoritamab-bysp (Epkinly), is indicated for use in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after 2 or more lines of systemic therapy based on finding from EPCORE NHL-1 (NCT03625037) .1 In the phase 2 study, treatment with subcutaneous epcoritamab led to deep and…

mi-viri Key competitor update & our take: Sparsentan falters as expected On May 1st, Travere Therapeutics (TVTX) announced disappointing data from their DUPLEX Phase 3 study focusing on FSGS. The study did not achieve the primary efficacy endpoint for eGFR slope over a 108-week treatment period in a statistically significant…

PRESS RELEASE Published May 19, 2023 The global progressive familial intrahepatic cholestasis type 2 treatment market size was valued at USD 35 million in 2021 and is projected to reach around USD 550 million in 2030 exhibiting a CAGR of 39.0% in the forecasted period.  Introduction The Global Progressive Familial…

In this issue of Blood, Roddie et al report results from the phase 1 ALEXANDER trial using a novel bicistronic anti-CD19 and anti-CD22 dual-targeted autologous chimeric antigen receptor (CAR) T-cell product, AUTO3, in combination with pembrolizumab, as a third-line or later treatment in patients with relapsed/refractory large B-cell lymphomas (LBCLs).1 Currently…

Diffuse large B-cell lymphoma (DLBCL) made headlines earlier this year with the high-profile case of prominent U.S. Congressman Jamie Raskin (D-MD). Yet, until very recently, progress in treating this most common form of lymphoma has been stalled for more than 2 decades. Significant breakthroughs have come in just the past…

On May 17, 2023, AstraZeneca announced positive findings from the Phase 3 FLAURA2 trial of Tagrisso (osimertinib) combined with chemotherapy for locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor mutations. The study demonstrated that Tagrisso and chemotherapy together resulted in a significant improvement in…

The Genomics Research Center (GRC) is a center of excellence for genetics and genomics that supports both Discovery and Development. The GRC plays an integral role towards our goal of developing extraordinary genetics and genomics research, focusing on finding the right targets and helping us better understand not only human…

  Post Hoc Analyses of Phase 2 Study of Crinecerfont in Adults with CAH Demonstrate Androgen Reduction Across a Broad Range of Glucocorticoid Doses Post Hoc Analyses of Phase 3 Study Demonstrate EFMODY® (hydrocortisone modified-release hard capsules) Reduced Androgen Levels Compared to Immediate-Release Hydrocortisone in…

PRESS RELEASE Published May 12, 2023 (New York, USA) DelveInsight’s “Diffuse Large B-cell Lymphoma (DLBCL) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Diffuse Large B-cell Lymphoma (DLBCL), historical and forecasted epidemiology as well as the Diffuse Large B-cell Lymphoma (DLBCL) market trends in the United…

The sellside expects a bumper year for blockbuster approvals, a recent Evaluate Vantage analysis revealed, but which products are creating all the excitement? A handful of significant new agents have already been approved, in Alzheimer’s disease, geographic atrophy and respiratory syncytial virus, and there is no shortage of pending regulatory…

PRESS RELEASE Published May 11, 2023 Biotechnology is the application of scientific and engineering principles to the processing of materials by biological agents to provide goods and services. Today, biotechnology is being used to create new and improved crop varieties, develop renewable fuels, and create new industrial and consumer products….

May 10, 2023 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2023 Highlights Genmab revenue increased 35% compared to the first quarter of 2022, to DKK 2,854 million “In the first quarter of the year we continued to lay the groundwork for the potential approval of epcoritamab…

PRESS RELEASE Published May 10, 2023 “Diffuse Large B-cell Lymphoma (DLBCL) Market” (New York, USA) DelveInsight’s “Diffuse Large B-cell Lymphoma (DLBCL) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Diffuse Large B-cell Lymphoma (DLBCL), historical and forecasted epidemiology as well as the Diffuse Large B-cell Lymphoma…

Diffuse Large B-cell Lymphoma (DLBCL) Market (New York, USA) DelveInsight’s “Diffuse Large B-cell Lymphoma (DLBCL) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Diffuse Large B-cell Lymphoma (DLBCL), historical and forecasted epidemiology as well as the Diffuse Large B-cell Lymphoma (DLBCL) market trends in the United…

CytomX Therapeutics Inc. – Continued progress in Phase 1 dose escalation for CX-904 (EGFRxCD3) – – IND enabling activities on track for filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) in the second half of 2023 – – Bristol Myers Squibb advances Anti-CTLA-4 non-fucosylated Probody®, BMS-986288, from Phase 1…

vadimrysev Investment Overview ImmunoGen (NASDAQ:IMGN) – an under the radar, Waltham, Massachusetts based biotech founded in 1981 sent its shareholders into raptures yesterday after publishing new data from its Phase 3 MIRASOL study of its drug ELAHERE, in patients with FRα-Positive, Platinum-Resistant Ovarian Cancer (“PROC”). Prior to yesterday’s news, ImmunoGen…

PRESS RELEASE Published May 1, 2023 DelveInsight’s, “Migraine Pipeline Insight 2023” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the Migraine pipeline landscape. It covers the Migraine pipeline drug profiles, including Migraine clinical trials and nonclinical stage products. It also covers the Migraine pipeline therapeutics assessment…

PRESS RELEASE Published April 28, 2023 As per the study initiated by Evolve Business Intelligence, the global Stem Cell Manufacturing market size accounted for USD 12.10 Billion in 2022, growing at a CAGR of 9.41% from 2023 to 2033. Stem cell manufacturing involves the production of stem cells on a…

Home Bioconductor 3.17 Released April 26, 2023 Bioconductors: We are pleased to announce Bioconductor 3.17, consisting of 2230 software packages, 419 experiment data packages, 912 annotation packages, 27 workflows and 3 books. There are 79 new software packages, 7 new data experiment packages, no new annotation packages, 2 new workflows,…

*Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma *The recommendation is based on results from the phase I/II NP30179 study, where Columvi given as a fixed course induced early and long-lasting complete responses in people with heavily…

Patricia Pozo-Rosich, MD, PhD Weeks after the FDA expanded the indication for atogepant (Qulipta; AbbVie) to include the treatment of chronic migraine, findings presented at the 2023 American Academy of Neurology (AAN) Annual Meeting, held April 22-27, in Boston, Massachusetts, further supported its efficacy. The data presented was from the…

Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma The recommendation is based on results from the phase I/II NP30179 study, where Columvi given as a fixed course induced early and long-lasting complete responses in people with heavily…

Researchers at Ludwig-Maximilians-Universität München (LMU) in Germany have discovered a weakness in the bacterium Helicobacter pylori, which could be exploited to develop new drugs.H. pylori, a pathogen responsible for widespread illnesses such as gastric ulcers and stomach cancer, has a weak point, which could be exploited to create new drugs….

PRESS RELEASE Published April 25, 2023 DelveInsight’s “Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Diffuse Large B-cell Lymphoma. DelveInsight’s “Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Diffuse Large B-cell Lymphoma,…

PRESS RELEASE Published April 24, 2023 DelveInsight’s, “Diffuse Large B-Cell Lymphoma Pipeline Insight 2023” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the Diffuse Large B-Cell Lymphoma pipeline drug profiles, including Diffuse Large B-Cell Lymphoma clinical trials…

Patricia Pozo-Rosich, MD, PhD AbbVie recently announced positive data from its phase 3 global, randomized, double-blind, placebo-controlled trial ELEVATE (NCT04740827), investigating atogepant (Qulipta) for preventive treatment of episodic migraine in adult patients who had previously failed 2 to 4 classes of oral preventive medications.1 Among 309 participants enrolled, 56% had…

LifeArc is inviting applications from academic institutions for its latest £40 million ($49.8 million) initiative to fund four or five new Translational Rare Disease Centres in the U.K., along with a separate co-ordinating hub. LifeArc, which is a self-funded, non-profit medical research charity, specializes in early-stage translation – the advancement…

NORTH CHICAGO – AbbVie (NYSE: ABBV) today announced positive data from its Phase 3 ELEVATE study, evaluating atogepant for the preventive treatment of episodic migraine in people who had previously failed two to four classes of oral preventive medications. The results of the study demonstrated adult patients in the atogepant…

By Marjorie E. Zettler, Ph.D., MPH, executive director of clinical science, Regor Pharmaceuticals, Inc. On April 6, AbbVie announced that it was voluntarily withdrawing ibrutinib from the U.S. market for two indications: mantle cell lymphoma (MCL, for patients who have received at least one prior therapy) and marginal zone lymphoma…

MT Newswires 2023 All news about ABBVIE INC. Analyst Recommendations on ABBVIE INC. Sales 2023 52 648 M – – Net income 2023 11 591 M – – Net Debt 2023 46 740 M – – P/E ratio 2023 24,2x Yield 2023 3,68% Capitalization 285 B 285 B – EV / Sales 2023 6,31x…

Subscribe to email alerts Stay up to date on recent news, articles, and more by subscribing to email alerts for one or more…

Roche RHHBY announced that the FDA has approved Polivy (polatuzumab vedotin-piiq) in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International…

Roche (RHHBY Quick QuoteRHHBY – Free Report) announced that the FDA has approved Polivy (polatuzumab vedotin-piiq) in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL)…

South San Francisco is known as the birthplace of biotechnology, after Robert Swanson and Dr. Herbert Boyer founded biotech giant Genentech in 1976, eventually leading to other biotech companies and pharmaceutical companies basing themselves in the local area. In this article, we take a look at six biotech companies currently…

Polivy combination is the first FDA-approved therapy in nearly 20 years for the first-line treatment of diffuse large B-cell lymphoma, an aggressive disease and the most common form of non-Hodgkin lymphoma in the US POLARIX trial showed the Polivy combination reduced the risk of disease progression, relapse or death by…

Results of a survey suggest that physicians treating patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in the third line prefer treatments that show efficacy, alignment with patient preferences, and capacity for outpatient administration. Survey results were presented in a poster at the 2023 NCCN Annual Conference by Wei…

PRESS RELEASE Published April 17, 2023 The Insight Partners Latest Research on “Vectorized Antibodies for In Vivo Expression Market Forecast to 2028″ Includes COVID-19 Impact and Global Analysis By Technology (Adeno associated Virus (AAV) Vector, Electroporation, Lipid Nanoparticles (LNPs)); End User (Research Institute, Hospitals, Others) and Geography Vectorized Antibodies is…

Intellia Therapeutics, Inc. CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced the appointment of Bill Chase, MBA, to its board of directors. Mr. Chase will be a member of…

Pictured: a scientist working on machine learning models/gorodenkoff/iStock As the number of employees laid off in the tech industry continues to grow, biopharma companies are increasingly recruiting talent who wish to transfer their skills to the life sciences.  Specifically, those with skills in artificial intelligence (AI) and machine learning (ML)…

The Genomics Research Center (GRC) is a center of excellence for genetics and genomics that supports both Discovery and Development. The GRC plays an integral role towards our goal of developing extraordinary genetics and genomics research, focusing on finding the right targets and helping us better understand not only human…

Abstract Cas12a CRISPR technology, unlike Cas9, allows for multiplexing guide RNAs from a single transcript, simplifying combinatorial perturbations. While Cas12a has been implemented for multiplexed knockout genetic screens, it has yet to be optimized for CRISPR activation (CRISPRa) screens in human cells. Here we develop a new Cas12a-based transactivation domain…

April 13, 2023 3 min read Source/Disclosures Published by: Source: Gao W, et al. Abstract HSR23-118. Presented at: NCCN Annual Conference; March 31-April 2, 2023; Orlando. Disclosures: AbbVie and Genmab sponsored this study. Lahue reports employment with Alkemi and an advisory board role with EvoEndo. Please see…

Antibody-drug conjugates (ADCs) are oncology drugs that have been compared to guided missiles because they home in on certain cell-surface targets and then unleash toxic chemotherapy drugs to battle cancer cells. They are not new. The FDA approved the first ADC more than 20 years ago, and drug developers have…

CEL-SCI’s revolutionary advances are impressive; their data shows that overall survival increased by almost 4 years, and some tumors even dissipated after a mere three weeks of Multikine therapy. The passionate group at CEL-SCI is completing the necessary confirmations for their manufacturing plant with efficiency while collaborating closely with the…

Janssen and AbbVie are voluntarily withdrawing the accelerated approvals of Imbruvica® (ibrutinib) for mantle cell lymphoma (MCL) in patients who have received at least 1 prior therapy, and for marginal zone lymphoma (MZL) in patients who require systemic therapy and have received at least 1 prior anti-CD20-based therapy, due to…

Caribou Biosciences is a biopharma company that has proprietary chRDNA (CRISPR hybrid RNA-DNA) technology, which allows for the creation of genome-edited cell therapies. One of the products of this technology, CB-011, was provided Fast Track designation by the US Food and Drug Administration (FDA). The treatment candidate is being evaluated…

Marché du traitement du lymphome non hodgkinien à cellules B, marché du traitement du lymphome non hodgkinien à cellules B 2028, industrie du traitement du lymphome non hodgkinien à cellules B, secteur du traitement du lymphome non hodgkinien à cellules B, traitement du lymphome non hodgkinien à cellules B PDF…

Competing interests A.R. is a founder, equity owner, and consultant at Halo Solutions and has served as a consultant at Tyra Biosciences. J.F.G. has served as a compensated consultant or received honoraria from Bristol Myers Squibb, Genentech/Roche, Ariad/Takeda, Loxo/Lilly, Blueprint, Oncorus, Regeneron, Gilead, Moderna, Mirati, AstraZeneca, Pfizer, Novartis, iTeos, Nuvalent,…

PRESS RELEASE Published April 5, 2023 Epithelial Ovarian Cancer Drugs market research is a report that is the result of careful investigation into relevant and useful data. The data that was examined took into account both existing top players and potential new competitors. Epithelial Ovarian Cancer Drugs the leading companies’…

AbbVie’s Genomics Research Center Computational Genomics is looking for a highly motivated computational biologist (Senior Scientist I/II, Bioinformatics) to join a team of bioinformatics scientists investigating aging and age-related diseases. AbbVie’s GRC is a center of excellence for bioinformatics, functional genomics, and human genetics. The GRC works across all R&D…

Developing treatments for neurological diseases presents a huge challenge for neuroscience companies within the biotech industry. The central nervous system (CNS) is extremely complex and many neurological diseases can be difficult to treat due to the limited regenerative capacity of the CNS, and the fact that the blood-brain barrier –…

This episode of the podcast is an in-depth look at antibody drug conjugates (ADCs). Our guests are Dr Pini Tsukerman, CEO of Nectin Therapeutics, and Matthew Robinson, chief technology officer of Immunome. This episode of the podcast is sponsored by PHTA. Immunome Immunome’s Discovery Engine leverages the information stored in…

In adults with moderately to severely active ulcerative colitis, treatment with risankizumab resulted in clinical remission and an improvement in symptoms, according to findings from the phase 3 INSPIRE induction study. The multicenter, randomized, double-blind, placebo-controlled INSPIRE study (ClinicalTrials.gov Identifier: NCT03398148) included 975 patients with moderately to severely active ulcerative…

AbbVie announced that its drug therapy upadacitinib (also known as RINVOQ®) is entering Phase 3 clinical trial for treatment of lupus. RINVOQ is already approved for the treatment of other autoimmune conditions, such as rheumatoid arthritis, psoriatic arthritis, and eczema. In the M19-130 Phase 2 trial of RINVOQ, the drug…

CytomX Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., March 22, 2023 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it will report full year 2022 financial results on Monday, March 27, 2023, after the close of U.S. markets. Following…

CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update – Internal focus on next generation therapeutic pipeline including ongoing Phase 1 for CX-904 (EGFRxCD3) and anticipated IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) in the second half of 2023 – – Bristol Myers Squibb…

– Internal focus on next generation therapeutic pipeline including ongoing Phase 1 for CX-904 (EGFRxCD3) and anticipated IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) in the second half of 2023 – – Bristol Myers Squibb advances Anti-CTLA-4 non-fucosylated Probody®, BMS-986288, from Phase 1 to Phase 2 clinical…

Keratosis Pilaris Treatment Market Is Expected to rise at A CAGR Of 4.26% during the forecast period 2023 to 2031: Growth Plus Reports Newark, New Castle, USA, March 20, 2023 (GLOBE NEWSWIRE) — The global keratosis pilaris treatment market will register a revenue CAGR of 4.26%, owing to the high…

March 19, 2023 2 min read Source/Disclosures Published by: Source: Simpson E. Dupilumab treatment in patients with hand and foot atopic dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial. Presented at: American Academy of Dermatology Annual Meeting; March 17-21, 2023; New Orleans. Disclosures: Eichenfield reports…

This article was updated by Willow Shah-Neville on March 17, 2023. Shamrocks, leprechauns, rolling green fields and Guinness beer all quickly bring Ireland to mind. Beyond these postcard-ready images, Ireland has an economy on the upswing and is a preferred destination for some big pharmas. But what about biotech? Here we explore…